Stockscreener 앱 받기
8.94
1.22%
-0.11
시간 외 거래:
8.94
전일 마감가:
$9.05
열려 있는:
$8.98
하루 거래량:
147.39K
Relative Volume:
0.74
시가총액:
$156.92M
수익:
$1.54M
순이익/손실:
$-38.70M
주가수익비율:
-1.9143
EPS:
-4.67
순현금흐름:
$-36.86M
1주 성능:
-6.78%
1개월 성능:
+16.41%
6개월 성능:
-22.26%
1년 성능:
+48.26%
1일 변동 폭
$8.5611
$9.07
1주일 범위
$8.5611
$10.12
52주 변동 폭
$4.64
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
명칭
Corbus Pharmaceuticals Holdings Inc
전화
617-963-0103
주소
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
8.94 | 158.85M | 1.54M | -38.70M | -36.86M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-30 | 재개 | B. Riley Securities | Buy |
| 2025-02-28 | 개시 | William Blair | Outperform |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 개시 | Wedbush | Outperform |
| 2024-07-22 | 재개 | H.C. Wainwright | Buy |
| 2024-06-26 | 개시 | B. Riley Securities | Buy |
| 2024-06-03 | 재확인 | Oppenheimer | Outperform |
| 2024-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2024-03-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-08 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-09-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-09-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-07-07 | 개시 | ROTH Capital | Buy |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-03-26 | 개시 | Nomura | Buy |
| 2019-04-05 | 개시 | Jefferies | Buy |
| 2019-03-20 | 개시 | Oppenheimer | Outperform |
| 2019-01-11 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-12-26 | 개시 | H.C. Wainwright | Buy |
| 2018-12-07 | 개시 | RBC Capital Mkts | Outperform |
| 2018-10-24 | 개시 | B. Riley FBR | Buy |
| 2018-01-19 | 개시 | Raymond James | Outperform |
| 2017-12-14 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-11-08 | 재확인 | Noble Financial | Buy |
| 2017-09-29 | 재개 | Noble Financial | Buy |
| 2017-03-30 | 재확인 | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-11-11 | 재확인 | Noble Financial | Buy |
모두보기
Corbus Pharmaceuticals Holdings Inc 주식(CRBP)의 최신 뉴스
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit - The Manila Times
Obesity drug from Corbus shows rapid weight loss in early trial - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Prosight Management LP Decreases Stock Position in Corbus Pharmaceuticals Holdings, Inc. $CRBP - MarketBeat
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Dermatomyositis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Octapharma, Argenx, AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharma, Holdings - Barchart
Dermatomyositis Market: Strong Pharma Growth Forecast Through - openPR.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
HC Wainwright Issues Negative Forecast for CRBP Earnings - MarketBeat
Trading Systems Reacting to (CRBP) Volatility - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Medpace Holdings (MEDP), Revolution Medicines (RVMD) and Corbus Pharmaceuticals (CRBP) - The Globe and Mail
Corbus Pharmaceuticals (NASDAQ: CRBP) files $300M shelf registration - Stock Titan
How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33% - Yahoo Finance
Research Analysts Offer Predictions for CRBP FY2030 Earnings - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price Expected to Rise, Oppenheimer Analyst Says - MarketBeat
Oppenheimer Raises Price Target for Corbus Pharmaceuticals (CRBP) to $57 | CRBP Stock News - GuruFocus
Corbus Pharmaceuticals Holdings, Inc. 2024 Annual Report: Pipeline, Intellectual Property, Regulatory Overview, and Business Strategy - Minichart
Corbus Pharmaceuticals (CRBP) Beats Q4 EPS Estimates - GuruFocus
Corbus Pharmaceuticals (NASDAQ: CRBP) details 2025 losses, cash and key trial data - Stock Titan
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results, Highlights Promising CRB-701 and CRB-913 Clinical Updates and Extends Cash Runway Into 2028 - Minichart
Corbus Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Q4 and annual financial update released, Corbus Pharmaceuticals Holdings, Inc. outlines - Traders Union
Corbus Pharmaceuticals 2025 Financials: Q4 Loss of $20.6M, Beats EstimatesNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Corbus Pharmaceuticals Highlights 2025 Results and Pipeline Progress - TipRanks
Corbus Pharmaceuticals: Fourth Quarter Financial Results Overview - Bitget
Corbus Pharmaceuticals (NASDAQ:CRBP) Releases Quarterly Earnings Results - MarketBeat
Corbus Pharmaceuticals (CRBP) Eyes Breakthroughs with CRB-701 an - GuruFocus
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update - Bitget
CORBUS PHARMACEUTICALS HLDGS ($CRBP) Releases Q4 2025 Earnings - Quiver Quantitative
Corbus Pharmaceuticals: Q4 Earnings Snapshot - marketscreener.com
Corbus Pharmaceuticals Q4 Earnings Summary & Key Takeaways - Benzinga
CRBP: Strong clinical progress and financing position support continued development into 2028 - TradingView
Corbus Pharmaceuticals (NASDAQ: CRBP) widens 2025 loss but boosts cash and pipeline progress - Stock Titan
Income Plays: Can Corbus Pharmaceuticals Holdings Inc ride the EV waveMarket Movement Recap & Daily Entry Point Trade Alerts - baoquankhu1.vn
Buyout Rumor: How is Corbus Pharmaceuticals Holdings Inc managing supply chain issuesJuly 2025 Action & Real-Time Sentiment Analysis - baoquankhu1.vn
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Corbus (NASDAQ: CRBP) CMO offloads shares in tax-related RSU sale - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals (CRBP) to Release Quarterly Earnings on Tuesday - MarketBeat
Insider sale notice — CRBP (NASDAQ: CRBP) lists 12,500 RSUs - Stock Titan
How Corbus Pharmaceuticals Holdings Inc. (CRBP) Affects Rotational Strategy Timing - Stock Traders Daily
Aug Movers: Can Corbus Pharmaceuticals Holdings Inc maintain its current growth rateJuly 2025 Action & AI Powered Market Trend Analysis - baoquankhu1.vn
Fund Flows: Can Corbus Pharmaceuticals Holdings Inc maintain its current growth rate2025 Buyback Activity & Fast Momentum Stock Entry Tips - baoquankhu1.vn
CRBP Should I Buy - Intellectia AI
Corbus Pharmaceuticals Holdings, Inc. advances CRB-701 for Nectin-4 solid tumors in early-stage development - Traders Union
Corbus Pharmaceuticals Touts “Catalyst-Rich” 2026 With CRB-701 and CRB-913 Data Readouts Ahead - MarketBeat
Corbus Highlights Diversified Oncology and Metabolic Pipeline Outlook - The Globe and Mail
EDGAR Filing Documents for 0001193125-26-068566 - SEC.gov
Corbus updates corporate presentation, details 2026 clinical and financial milestones - TradingView
Corbus Pharmaceuticals Holdings Inc (CRBP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):